Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed / Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma

This study will enroll approximately 160 adult subjects who have relapsed or refractory (r / r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds to this experimental product and if this product is safe. Axicabtagene ciloleucel is made from the subjects own white blood cells which are genetically modified and grown to fight cancer. An objective response rate of 70% is targeted.
Lymphoma
II
Oluwole, Olalekan
NCT03105336
VICCBMT1844

Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma

Lymphoma

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in participants with high-risk large B-cell lymphoma.
Lymphoma
II
Oluwole, Olalekan
NCT03761056
VICCBMT18146

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: